Physician profile
John M Bray
NPI 1811972359
$2,273.82
in general payments reported to CMS, 2019-2025
28 companies · $83.02 in 2025
The $83.02 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,404 · 2020: $196 · 2021: $151 · 2022: $152 · 2023: $135 · 2024: $153 · 2025: $83.02.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $371.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $371.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Electromed, INC. | $529.52 | 2019-2025 | Smartvest |
| Glaxosmithkline, LLC. | $277.71 | 2019-2020 | |
| Genentech USA, INC. | $190.95 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $157.01 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $139.91 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $136.26 | 2019-2021 | |
| Allergan, INC. | $120.60 | 2019 | |
| Philips North America LLC | $73.94 | 2019-2020 | |
| Inspire Medical Systems, INC. | $69.25 | 2023-2024 | Inspire |
| Merck Sharp & Dohme LLC | $68.40 | 2019 | |
| Genzyme Corporation | $63.75 | 2019 | |
| Insmed, INC. | $62.73 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $58.39 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $51.13 | 2019 | |
| Mallinckrodt Hospital Products INC. | $39.28 | 2023 | Acthar |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $29.01 | 2019-2020 | |
| Vapotherm INC | $27.47 | 2022 | |
| Mylan Specialty L.P. | $24.54 | 2020 | |
| Grifols USA, LLC | $21.07 | 2020 | |
| 3b Medical, INC. | $18.96 | 2024 | Luna |
| Mallinckrodt Enterprises LLC | $17.30 | 2019 | |
| Resmed Corp | $16.69 | 2025 | |
| Abbvie INC. | $13.79 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.45 | 2019 | |
| Gilead Sciences, INC. | $13.45 | 2019 | |
| Jazz Pharmaceuticals INC. | $13.43 | 2019 | |
| Cook Medical LLC | $13.29 | 2019 | |
| Janssen Pharmaceuticals, INC | $12.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Bray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.